4,4′-Bis(2-Bromoacetyl) biphenyl CAS 4072-67-7

Description:

Nomen chemicum: 4,4′-Bis(2-Bromoacetyl) biphenyl

CAS: 4072-67-7

Puritas: >98.0% (HPLC)

Intermedia Daclatasvir Dihydrochloride CAS 1009119-65-6

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

4072-67-7 - Descriptio:

Shanghai Ruifu Chemical Co., LtdRuifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase 4,4'-Bis(2-Bromoacetyl) biphenyl,Please contact: alvin@ruifuchem.com

4072-67-7 - Chemical Properties:

Nomen chemicum 4,4'-Bis(2-Bromoacetyl) biphenyl
Synonyma 4,4'-Bis (Bromoacetyl) biphenyl;1,1'-[1,1'-Biphenyl]-4,4'-diylbis[2-Bromoethan-1-one];Daclatasvir Impurity 7
Stock Status In Stock, Commercial Productio
CAS Number 4072-67-7
Formulae hypotheticae C16H12Br2O2
M. Pondus 396.07 g/mol
Liquescens punctum 226.0~227.0℃
Density 1.622±0.06 g/cm3
COA & MSDS Praesto
Origin Shanghai, China
Categoria Intermedia Daclatasvir Dihydrochloride (CAS: 1009119-65-6)
Brand Ruifu Chemical

4072-67-7 - Formulae:

Items Specifications Proventus
Aspectus Firmus Firmus
Puritas / Analysis Methodus >98.0% (HPLC) 98.5%
Infrared Imaginis Congruunt Structure Obsequitur
1H NMR Imaginum Congruunt Structure Obsequitur
conclusio Productum probatum est et cum datis specificationibus obsequitur
Applicationem Intermedia Daclatasvir Dihydrochloride (CAS: 1009119-65-6)

Sarcina / at /naviportans:

Sarcina:Fluorinated Utrem, aluminium ffoyle, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Continentem arcte clausam et in frigido, sicco et bene ventilato horreis a substantiis incompossibilibus repone.A luce et humore protege.
Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.

commoda:

Satis capacitas: sufficientes facilities et technici

Professional Service: One stop acquireing service

Altera Package: Custom sarcina ac titulus praesto

Ieiunium Delivery: Si intra stirpem, tres dies partus praestatur

Supple firmum: Esse rationabile stirpe

Technical Support: Technology solution praesto

Custom Synthesis Service: Range from P. to kilos

High Quality: Constitutus ratio completa qualitas certitudinis

FAQ:

Quam mercari?Quaeso contactumDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com 

15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.

Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Coream, Iaponicam, Australiam etc.

Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.

Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.

Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.

Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.

MOQ?Nec MOQ.Parvus ordo placet.

Tempus adferendi? Si intus prosapia, tres dies partus praestatur.

Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.

Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.

Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.

Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.

4072-67-7 - Applicatio:

4,4'-Bis(2-Bromoacetyl) biphenyl (CAS: 4072-67-7) est medius Daclatasvir Dihydrochloridis (CAS: 1009119-65-6).
Daclatasvir Dihydrochloridis (Daklinza) est inhibitor viri hepatitis C (HCV) NS5A quod utile est in curatione genotypi 3 hepatitis chronici C infectionis.
Die 24 mensis Iulii anno 2015, FDA chronica hepatitis C medicamentis (Bristol-Myers Squibb) probata est.
FDA approbatio processus Daklinzae (Squibb Bristol-Myers) supinationes et vices subiit.Semel ab FDA repudiatum est, sed tandem in medio-2015 probatus est.FDA approbavit coniunctionem Daklinza et Sofosbuvir ad curationem generis genericis hepatitis C 3 aegros.
Revera, primo ac ante FDA approbante, Daklinza probata est in Iaponia, in Unione Europaea et Corea Meridiana aliisque regionibus.Anno 2014, pars sanitatis Iaponica applicationem Daklinza et Asunaprevir (Sunvepra) ad tractationem genotypi 1 infectionis approbavit.Unio Europaea etiam Daclatasvir probavit utendum cum aliis medicamentis in tractatione genotyporum HCV 1, 2, 3, 4 anno 2014. Daclatasvir primus est NS5A complexus inhibitor ab Unione Europaea approbatus (EU).Cum usus in compositione cum aliis medicamentis, collatis cum curatione compositionis interferonis et ribavirin quae accipit 48 septimanas, breviorem durationem habet curationum (12 hebdomades vel 24 septimanas).
Monotherapia Daclathavir non commendatur, protocollum vena amet compositum therapia Dacastavir+ Sofosbuvir, quae bona efficacia propria est, altior SVR, minoris lateris effectus et cycli curationis ulterioris optiones abbreviatae.

Epistulam tuam hic scribe et mitte nobis